Infectious Diseases

Rethinking C. diff Treatment: Is Fidaxomicin Worth the Money?

The TAPER-V trial forces us to ask a question we should have been asking all along — would fidaxomicin have demonstrated superiority if the original trials had used longer follow-up?

Infectious Diseases Volume 1, Issue 1

The First Oral Carbapenem Arrives - Tebipenem pivoxil (Utebzi): what it is, where it earns its place, and where it absolutely does not

Baxdrostat vs. Spironolactone: A New Mechanism Meets an Old Bargain - THE $5-BILLION QUESTION

IV Iron in Oncology: Time to Rethink Your Default

When the New β-Lactam/β-Lactamase Inhibitors Aren’t Enough

PharmaCompass InPHARMation is for educational purposes only and does not constitute medical advice. Always verify clinical information before applying to patient care. Full Disclaimer | © 2026 PharmaCompass Education, LLC

Read more

The First Oral Carbapenem Arrives - Tebipenem pivoxil (Utebzi): what it is, where it earns its place, and where it absolutely does not

Baxdrostat vs. Spironolactone: A New Mechanism Meets an Old Bargain - THE $5-BILLION QUESTION

IV Iron in Oncology: Time to Rethink Your Default

When the New β-Lactam/β-Lactamase Inhibitors Aren’t Enough